Friday, July 25, 2008

But is it Worth it?

Good news.

There is a new drug in the fight against liver cancer. Most drugs do not work on liver cancer so this is a breakthrough.

The bad news.

Nexavar runs $5,400 per month.

So who pays?

All of us.

So what does the patient gain by using this new drug?

Average life expectancy without the drug . . . 7.9 months.

Average life expectancy for those using the drug . . . 10.7 months.

Is trading $15,000 for 3 months worth it?

This is a question all of us will have to ask.

0 comments:

Post a Comment